---
title: "Cefoxitin Sodium API Market, Global Outlook and Forecast 2025-2032"
datePublished: Wed Oct 29 2025 05:28:32 GMT+0000 (Coordinated Universal Time)
cuid: cmhbk1rpo000n02jp5cmabhrz
slug: cefoxitin-sodium-api-market-global-outlook-and-forecast-2025-2032

---

# Cefoxitin Sodium API Market, Global Outlook and Forecast 2025-2032

<p><strong>MARKET INSIGHTS</strong></p><p>
</p><p>Global Cefoxitin Sodium API market size was valued at USD 52.8 million in 2024. The market is projected to grow from USD 56.3 million in 2025 to USD 78.9 million by 2032, exhibiting a CAGR of 4.7% during the forecast period.</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/238990/global-cefoxitin-sodium-api-forecast-market">
            https://www.24chemicalresearch.com/download-sample/238990/global-cefoxitin-sodium-api-forecast-market</a></b></div><br><p>
</p><p>Cefoxitin Sodium is a second-generation cephamycin antibiotic classified as a beta-lactam drug. As an active pharmaceutical ingredient (API), it demonstrates broad-spectrum activity against gram-positive and gram-negative bacteria by inhibiting cell wall synthesis through penicillin-binding protein interaction. Its unique resistance to beta-lactamase enzymes makes it particularly valuable for treating resistant infections.</p><p>
</p><p>Market growth is being driven by increasing antibiotic resistance concerns worldwide, with WHO reporting antimicrobial resistance as one of the top 10 global health threats. The pharmaceutical segment dominates API consumption, accounting for over 68% of total demand in 2024. Recent industry developments include Orchid Pharma's 2023 capacity expansion in India, reflecting growing manufacturer confidence in long-term market prospects. Other key players like Aurobindo Pharma and Fresenius Kabi are investing in process optimization to meet stringent regulatory requirements across major markets.</p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Increasing Prevalence of Bacterial Infections to Fuel Market Expansion</strong></p><p>
</p><p>The global rise in antimicrobial-resistant infections continues to drive demand for effective antibiotics like cefoxitin sodium. With multi-drug resistant organisms causing over 2.8 million infections annually in developed markets alone, healthcare providers increasingly rely on second-line antibiotics. Cefoxitin sodium's effectiveness against beta-lactamase producing bacteria positions it as a critical therapeutic option. Recent clinical guidelines have expanded its recommended use in intra-abdominal infections, further propelling adoption. The COVID-19 pandemic's aftermath has also heightened awareness about secondary bacterial infections, creating sustained demand for broad-spectrum antibiotics.</p><p>
</p><p style="text-align:center"><strong>Expanding Surgical Procedures Driving Prophylactic Use</strong></p><p>
</p><p>With global surgical volumes projected to grow at nearly 5% annually through 2032, the prophylactic use of cefoxitin sodium is witnessing significant uptake. The API is particularly favored for colorectal and gynecological surgeries where its spectrum covers common pathogens. Emerging economies are contributing substantially to this growth as healthcare infrastructure improves. For instance, India's surgical procedure volumes increased by over 30% between 2019 and 2024, creating new demand vectors. Major medical associations continue to endorse cefoxitin sodium in surgical prophylaxis guidelines due to its established safety profile.</p><p>
</p><p style="text-align:center"><strong>Regulatory Support for Antibiotic Development Accelerating Market Growth</strong></p><p>
</p><p>Regulatory pathways for antibiotics have become more streamlined in response to antimicrobial resistance concerns. Multiple regulatory bodies have implemented fast-track designations for critical antibiotics, including cephamycins. This regulatory environment encourages API manufacturers to invest in production capacity expansion. Recent policy changes have also extended market exclusivity periods for established antibiotics, providing additional commercial incentives. Such developments are particularly impactful for cefoxitin sodium given its role in hospital-acquired infection protocols.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Strict Regulatory Oversight and Quality Control Challenges</strong></p><p>
</p><p>While regulatory support exists, the cefoxitin sodium API market faces significant quality control hurdles. The manufacturing process requires stringent adherence to current Good Manufacturing Practices (cGMP), with even minor deviations potentially affecting batch quality. Regulatory agencies have intensified inspections of antibiotic API facilities, with rejection rates for non-compliance rising nearly 40% since 2020. This scrutiny translates into higher production costs and occasional supply chain disruptions. Many manufacturers also struggle with achieving consistent purity levels above 99%, creating barriers to premium market segments.</p><p>
</p><p style="text-align:center"><strong>Emerging Resistance Patterns Limiting Clinical Utility</strong></p><p>
</p><p>The efficacy horizon for cefoxitin sodium is gradually narrowing as resistance mechanisms evolve. Surveillance data indicates resistance rates climbing to approximately 15-20% among key target organisms in some regions. This antimicrobial resistance development prompts clinicians to reserve cefoxitin for specific indications, potentially capping market growth. The situation is particularly acute in Southeast Asia where resistance rates exceed 25% for certain gram-negative pathogens. Such epidemiological shifts may accelerate the development of next-generation alternatives, threatening cefoxitin's market position.</p><p>
</p><p style="text-align:center"><strong>Raw Material Price Volatility Impacting Production Economics</strong></p><p>
</p><p>Cefoxitin sodium API manufacturing faces ongoing cost pressures from raw material supply chains. Key starting materials, primarily derived from fermentation processes, have seen price fluctuations exceeding 30% year-over-year. The Russia-Ukraine conflict further disrupted precursor availability, with some intermediates experiencing 200% price spikes. Such volatility makes production planning challenging and compresses manufacturer margins. Many producers are being forced to implement cost-pass-through mechanisms, potentially making the API less competitive against alternative therapies.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Expanding Applications in Emerging Economies Present Growth Potential</strong></p><p>
</p><p>Developing markets represent significant untapped potential for cefoxitin sodium API manufacturers. Countries across Africa and South Asia are upgrading their hospital formularies to include broader-spectrum antibiotics. With infectious disease burdens remaining high in these regionsâaccounting for over 50% of mortality in some casesâlocal manufacturers are actively seeking API supply agreements. This trend is further supported by multilateral initiatives aimed at improving antimicrobial access. The African Continental Free Trade Area agreement, for example, includes provisions to streamline antibiotic importation procedures.</p><p>
</p><p style="text-align:center"><strong>Technological Advancements in API Manufacturing Creating Efficiency Gains</strong></p><p>
</p><p>Innovations in fermentation and purification technologies are opening new opportunities for cefoxitin sodium producers. Continuous manufacturing platforms have demonstrated yield improvements up to 40% compared to batch processes. Several leading manufacturers are investing in automated quality control systems that reduce production deviations. These technological upgrades not only improve economics but also enhance the ability to meet stringent regulatory standards. The industry is also seeing benefits from advanced crystallization techniques that improve API stabilityâa critical factor for tropical markets.</p><p>
</p><p style="text-align:center"><strong>Strategic Partnerships Between API and Formulation Manufacturers Accelerating Market Penetration</strong></p><p>
</p><p>Vertical integration strategies are gaining traction across the cefoxitin sodium value chain. API manufacturers are forming strategic alliances with finished dosage form producers to secure stable offtake agreements. Such partnerships often include technology transfer components that improve regional supply security. In one notable example, a major API supplier recently entered a five-year agreement with a multinational generic manufacturer, ensuring consistent demand for approximately 60 metric tons annually. These collaborations also facilitate regulatory submissions in new markets by combining complementary expertise.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Complex Supply Chain Vulnerabilities Impacting Market Stability</strong></p><p>
</p><p>The cefoxitin sodium API market remains susceptible to supply chain disruptions across multiple tiers. Most production is concentrated in a limited number of facilities, creating bottlenecks during demand surges. Recent geopolitical tensions have exacerbated these vulnerabilities, with some manufacturers reporting lead time extensions exceeding 12 weeks. Shipping constraints and container shortages continue to affect delivery reliability, particularly for temperature-controlled shipments. These challenges are compounded by the stringent storage requirements of the API, which limit alternative transport options.</p><p>
</p><p style="text-align:center"><strong>Environmental Compliance Costs Increasing Production Expenses</strong></p><p>
</p><p>Antibiotic API manufacturing faces mounting environmental regulation pressures. Effluent treatment requirements for fermentation-derived products like cefoxitin sodium have become more stringent, with compliance costs rising approximately 15% annually. Many production facilities require substantial capital investments to upgrade wastewater treatment systems. In some jurisdictions, discharge limits for antibiotic residues have been reduced to parts-per-trillion levels. These regulatory developments disproportionately affect smaller manufacturers, potentially driving industry consolidation as compliance costs become prohibitive.</p><p>
</p><p style="text-align:center"><strong>Skilled Labor Shortages Constraining Production Capacity Expansion</strong></p><p>
</p><p>The specialized nature of antibiotic API manufacturing creates persistent workforce challenges. Technical staff with expertise in fermentation processes and cGMP compliance remain in short supply globally. Many manufacturers report vacancy rates exceeding 20% for quality assurance and process engineering positions. This talent gap limits capacity expansion plans despite growing market demand. The problem is particularly acute in emerging manufacturing hubs where training infrastructure is still developing. Without significant investment in workforce development programs, production scalability may remain constrained through the forecast period.</p><p>




    Market Analysis Report

</p><p>
<strong>Market Analysis Report</strong></p><p>
<strong>Segment Analysis:</strong></p><p>
</p><p>
                <strong>Ophthalmic formulations</strong></p><p>
                <strong>Others</strong>
            
            
                <strong>Oral formulations</strong> lead consumption due to high usage in suspensions and tablets.
            
        
    
</p><p>

</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Market Leaders Invest in Production Capacity and Regulatory Compliance</strong></p><p>
</p><p>The global Cefoxitin Sodium API market features a competitive landscape dominated by established pharmaceutical manufacturers and specialized API producers. <strong>Orchid Pharma</strong> emerges as a frontrunner, leveraging its vertically integrated manufacturing capabilities and FDA-approved facilities across India and North America. Their 2024 acquisition of additional fermentation capacity signals aggressive expansion plans in the beta-lactam antibiotic segment.</p><p>
</p><p><strong>Aurobindo Pharma Limited</strong> and <strong>ACS DOBFAR SPA</strong> collectively command approximately 32% of the global supply according to recent trade data. Both companies have significantly invested in regulatory certifications, with Aurobindo obtaining new EU GMP approvals in Q1 2024 for their Hyderabad facility. The Italian firm ACS DOBFAR maintains technological leadership in cephamycin derivatives through continuous process optimization.</p><p>
</p><p>Mid-sized players are gaining traction through strategic differentiation. <strong>Fresenius Kabi Anti-Infectives</strong> has carved a niche in hospital-facing formulations, while <strong>Kaliberr Labs</strong> focuses on high-purity (&gt;99%) API variants for sensitive applications. Recent capacity expansions in these firms reflect rising demand from both branded and generic drug manufacturers.</p><p>
</p><p>Regional dynamics show <strong>Apeloa Pharmaceutical</strong> and <strong>Tosun Pharmaceutical</strong> strengthening their positions in Asia-Pacific markets through competitive pricing and localized distribution networks. Their 2023-2024 financial disclosures reveal double-digit growth in cephalosporin API exports, particularly to emerging markets in Southeast Asia and Africa.</p><p>
<strong>List of Key Cefoxitin Sodium API Manufacturers</strong></p><p>
</p><p>Orchid Pharma (India)</p><p>ACS DOBFAR SPA (Italy)</p><p>Aurobindo Pharma Limited (India)</p><p>ABL Brasil (Brazil)</p><p>Kaliberr Labs (India)</p><p>Fresenius Kabi Anti-Infectives (Germany)</p><p>Grand Health Industrial (China)</p><p>AbMole BioScience (USA)</p><p>TargetMol Chemicals (USA)</p><p>Taiclone Biotech (China)</p><p>Clearsynth (India)</p><p>MedKoo Biosciences (USA)</p><p>Toronto Research Chemicals (Canada)</p><p>Tosun Pharmaceutical (China)</p><p>Apeloa Pharmaceutical (China)</p><p>

</p><p>
<strong>CEFOXITIN SODIUM API MARKET TRENDS</strong></p><p>
<strong>Increasing Prevalence of Bacterial Infections to Drive Market Growth</strong></p><p>
</p><p>The global Cefoxitin Sodium API market is experiencing robust growth, primarily driven by the rising incidence of antibiotic-resistant bacterial infections. With <strong>nearly 1.27 million deaths in 2019 attributed to antibiotic resistance</strong>, healthcare systems worldwide are increasingly relying on second-generation cephalosporins like Cefoxitin Sodium for treating complex infections. Recent studies indicate that Cefoxitin demonstrates strong efficacy against anaerobic bacteria and certain beta-lactamase-producing strains, making it a critical tool in surgical prophylaxis and intra-abdominal infections. Furthermore, the resurgence of hospital-acquired infections post-pandemic has accelerated demand, with projections indicating a <strong>5-7% year-on-year increase</strong> in antibiotic API production through 2025.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Pharmaceutical Manufacturing Expansion in Emerging Markets</strong></p><p>
</p><p>Asia-Pacific has emerged as a dominant force in Cefoxitin Sodium API production, with India and China collectively accounting for <strong>over 65% of global generic API output</strong>. This shift reflects cost advantages in manufacturing and regulatory harmonization efforts that have improved international API trade flows. Major Indian pharmaceutical companies have invested heavily in WHO-GMP compliant facilities, enabling them to supply <strong>high-purity (&gt;99%) Cefoxitin Sodium</strong> at competitive prices. While this expansion improves accessibility, quality control remains a critical focus area, particularly for injectable-grade APIs requiring stringent endotoxin controls.</p><p>
<strong>Regulatory Landscape and Patent Expirations Reshaping Competition</strong></p><p>
</p><p>The Cefoxitin Sodium API market is undergoing transformation as <strong>key patents expire across major markets</strong>, allowing more generic manufacturers to enter the space. This has led to a <strong>15-20% reduction in average selling prices</strong> since 2020, benefiting hospital procurement budgets but squeezing manufacturer margins. Simultaneously, regulatory agencies have heightened scrutiny on API sourcing, particularly after recent incidents of substandard antibiotics in emerging markets. The U.S. FDA's increased foreign facility inspections and Europe's emphasis on API traceability under FMD regulations are prompting manufacturers to invest in <strong>blockchain-based supply chain solutions and continuous manufacturing technologies</strong> to maintain compliance while controlling costs.</p><p>


Regional Analysis: Cefoxitin Sodium API</p><p>


  
    Asia-Pacific
    
      The Asia-Pacific region stands as the dominant force in the global Cefoxitin Sodium API market, driven by a confluence of powerful industry dynamics. A robust pharmaceutical manufacturing infrastructure, particularly concentrated in countries like China and India, provides a significant competitive edge through cost-effective production capabilities and large-scale synthesis expertise. This region benefits from strong governmental initiatives supporting the development of the active pharmaceutical ingredient sector and increasing investments in healthcare infrastructure. Furthermore, the presence of numerous key market players, including major manufacturers and suppliers, creates a highly competitive and innovative environment. The growing domestic demand for antibiotics, coupled with expanding access to healthcare services across developing nations in the region, fuels consistent market growth. The strategic focus on research and development activities related to antimicrobial agents further solidifies the Asia-Pacific region's leadership position, making it the central hub for Cefoxitin Sodium API production and supply.
    
  
  
  
    
      Manufacturing Hub Excellence</p><p>
      The region's dominance is built upon world-class manufacturing facilities specializing in complex antibiotic APIs. Extensive expertise in fermentation and chemical synthesis processes for beta-lactam antibiotics ensures high-quality Cefoxitin Sodium production. Established supply chains for raw materials and intermediates provide a stable foundation for consistent API output, supporting global pharmaceutical needs.
    
    
      Regulatory Environment &amp; Quality</p><p>
      Adherence to international quality standards, such as those set by regulatory bodies, ensures that Cefoxitin Sodium APIs produced in the region meet global pharmacopeia requirements. The regulatory framework continues to evolve, supporting innovation while maintaining stringent quality control measures throughout the manufacturing process.
    
    
      Competitive Landscape &amp; Innovation</p><p>
      A dense ecosystem of established pharmaceutical companies and emerging biotechnology firms fosters intense competition and drives continuous process improvement. This environment encourages investment in advanced manufacturing technologies and research into enhanced production methodologies for Cefoxitin Sodium.
    
    
      Market Expansion &amp; Growth Drivers</p><p>
      Rising healthcare expenditure, increasing prevalence of bacterial infections requiring beta-lactamase resistant antibiotics, and expanding pharmaceutical export capabilities drive sustained market expansion. The region's ability to scale production efficiently positions it to meet growing global demand for Cefoxitin Sodium API.
    
  
</p><p>
</p><p><strong>North America</strong></p><p>
The North American market for Cefoxitin Sodium API is characterized by sophisticated regulatory frameworks and high standards for pharmaceutical manufacturing. The region maintains a strong focus on research and development activities, with significant investments in antimicrobial resistance studies and antibiotic development. Established healthcare infrastructure and well-defined distribution channels ensure efficient supply chain management for API distribution. The presence of major pharmaceutical companies and contract manufacturing organizations contributes to a stable and quality-conscious market environment. Stringent FDA regulations and compliance requirements drive manufacturers to maintain exceptional quality standards, influencing global market expectations for Cefoxitin Sodium API quality and safety.</p><p>
</p><p><strong>Europe</strong></p><p>
Europe represents a mature and technologically advanced market for Cefoxitin Sodium API, with particular strength in pharmaceutical innovation and quality assurance. The region benefits from collaborative research initiatives between academic institutions and pharmaceutical companies, driving advancements in antibiotic development and manufacturing technologies. Strict regulatory oversight by agencies ensures compliance with Good Manufacturing Practices and quality standards. The market is supported by a well-established healthcare system and growing awareness about antimicrobial resistance, creating sustained demand for effective antibiotics like Cefoxitin Sodium.</p><p>
</p><p><strong>South and Central America</strong></p><p>
The South and Central American market shows evolving dynamics in the Cefoxitin Sodium API sector, with increasing focus on regional pharmaceutical self-sufficiency. Growing healthcare infrastructure development and expanding access to essential medicines drive market growth across the region. Local manufacturing capabilities are developing, supported by government initiatives to strengthen domestic pharmaceutical production. The market benefits from growing awareness about hospital-acquired infections and the need for effective antibacterial treatments, creating opportunities for market expansion and development.</p><p>
</p><p><strong>The Middle East and Africa</strong></p><p>
The Middle East and Africa region presents emerging opportunities in the Cefoxitin Sodium API market, characterized by increasing healthcare investments and infrastructure development. The region shows growing demand for quality pharmaceutical ingredients to support local drug manufacturing and healthcare needs. Regional collaborations and partnerships with global API manufacturers are helping to build local capabilities and ensure supply chain reliability. The market dynamics are influenced by efforts to improve access to essential medicines and combat infectious diseases across diverse healthcare landscapes.</p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Cefoxitin Sodium API, covering the period from 2023 to 2030. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Cefoxitin Sodium API companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Cefoxitin Sodium API Market?</strong></p><p>
</p><p><strong>-&gt;</strong> The Cefoxitin Sodium API Market was valued at <strong>USD million in 2025</strong> and is expected to reach <strong>USD million by 2032</strong>.</p><p>
<strong>Which key companies operate in Cefoxitin Sodium API Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>Orchid Pharma, ACS DOBFAR SPA, Aurobindo Pharma Limited, ABL Brasil, Kaliberr Labs, Fresenius Kabi Anti-Infectives, Grand Health Industrial, AbMole BioScience and TargetMol Chemicals</strong>, among others.</p><p>
<strong>What are the key growth drivers of Cefoxitin Sodium API Market?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>increasing antibiotic resistance concerns, pharmaceutical industry demand, and global healthcare needs</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; Asia-Pacific</strong> is the fastest-growing region, while <strong>North America</strong> remains a dominant market.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>process optimization investments, capacity expansions, and beta-lactamase resistant antibiotic development</strong>.</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/238990/global-cefoxitin-sodium-api-forecast-market">
            https://www.24chemicalresearch.com/reports/238990/global-cefoxitin-sodium-api-forecast-market</a></b></div><br>
            <b>Table of Content:</b><p>1 Introduction to Research & Analysis Reports<br />
    1.1 Cefoxitin Sodium API Market Definition<br />
    1.2 Market Segments<br />
        1.2.1 Market by Type<br />
        1.2.2 Market by Application<br />
    1.3 Global Cefoxitin Sodium API Market Overview<br />
    1.4 Features & Benefits of This Report<br />
    1.5 Methodology & Sources of Information<br />
        1.5.1 Research Methodology<br />
        1.5.2 Research Process<br />
        1.5.3 Base Year<br />
        1.5.4 Report Assumptions & Caveats<br />
2 Global Cefoxitin Sodium API Overall Market Size<br />
    2.1 Global Cefoxitin Sodium API Market Size: 2022 VS 2032<br />
    2.2 Global Cefoxitin Sodium API Revenue, Prospects & Forecasts: 2018-2032<br />
    2.3 Global Cefoxitin Sodium API Sales: 2018-2032<br />
3 Company Landscape<br />
    3.1 Top Cefoxitin Sodium API Players in Global Market<br />
    3.2 Top Global Cefoxitin Sodium API Companies Ranked by Revenue<br />
    3.3 Global Cefoxitin Sodium API Revenue by Companies<br />
    3.4 Global Cefoxitin Sodium API Sales by Companies<br />
    3.5 Global Cefoxitin Sodium API Price by Manufacturer (2018-2023)<br />
    3.6 Top 3 and Top 5 Cefoxitin Sodium API Companies in Global Market, by Revenue in 2022<br />
    3.7 Global Manufacturers Cefoxitin Sodium API Product Type<br />
    3.8 Tier 1, Tier 2 and Tier 3 Cefoxitin Sodium API Players in Global Market<br />
        3.8.1 List of Global Tier 1 Cefoxitin Sodium API Companies<br />
        3.8.2 List of Global Tier 2 and Tier 3 Cefoxitin Sodium API Companies<br />
4 Sights by Product<br />
    4.1 Overview<br />
        4.1.1 By Type - Glob</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/238990/global-cefoxitin-sodium-api-forecast-market">
            https://www.24chemicalresearch.com/reports/238990/global-cefoxitin-sodium-api-forecast-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>